Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
June 30, 2003
- FPMAJ Committee Proposes Revisions to NHI Pricing Rules
June 30, 2003
- Business Challenges Discussed: UBS Conference
June 30, 2003
- Meet the Leaders (21)
June 30, 2003
- DIAGNOSTIC NEWS IN BRIEF
June 30, 2003
- MEDICAL DEVICE NEWS IN BRIEF
June 30, 2003
- OTC NEWS IN BRIEF
June 30, 2003
- Ain Pharmaciez: Merger Contributes to Strong Growth in Sales, Profits
June 30, 2003
- BULLETIN
June 23, 2003
- Kuraya Sanseido to Cut Costs Without Undermining Marketing Ability
June 23, 2003
- WORLD NEWS IN BRIEF
June 23, 2003
- BUSINESS NEWS IN BRIEF
June 23, 2003
- Press Seminar
June 23, 2003
- WEBSITE NEWS
June 23, 2003
- MEDICAL DEVICE NEWS IN BRIEF
June 23, 2003
- NEW PRODUCTS
June 23, 2003
- DPO Recommends Exemption of Re-pricing for Useful Drugs
June 23, 2003
- Teikoku Hormone to Specialize in Endocrinology
June 23, 2003
- Semiannual Settlement
June 23, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
June 23, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…